Breaking News Instant updates and real-time market news.

ENTA

Enanta

$43.43

-0.07 (-0.16%)

, ADXS

Advaxis

$3.91

-0.36 (-8.43%)

04:55
09/27/17
09/27
04:55
09/27/17
04:55

Cantor Fitzgerald to hold a conference

Global Healthcare Conference is being held in New York on September 25-27.

ENTA

Enanta

$43.43

-0.07 (-0.16%)

ADXS

Advaxis

$3.91

-0.36 (-8.43%)

AWR

American States Water

$50.68

-0.8 (-1.55%)

CDTX

Cidara Therapeutics

$8.05

0.2 (2.55%)

GEMP

Gemphire Therapeutics

$9.60

-0.04 (-0.41%)

ARRY

Array BioPharma

$11.29

-0.03 (-0.27%)

AUPH

Aurinia Pharmaceuticals

$6.11

-0.07 (-1.13%)

NEOS

Neos Therapeutics

$8.40

-0.3 (-3.45%)

SELB

Selecta Biosciences

$18.66

-0.18 (-0.96%)

PTGX

Protagonist Therapeutics

$16.28

-0.11 (-0.67%)

ITCI

Intra-Cellular

$19.23

-0.57 (-2.88%)

BLCM

Bellicum Pharmaceuticals

$11.54

-0.08 (-0.69%)

CALA

Calithera Biosciences

$15.45

-0.5 (-3.13%)

INO

Inovio

$6.31

0.02 (0.32%)

PRTA

Prothena

$63.73

-0.64 (-0.99%)

  • 27

    Sep

  • 27

    Sep

  • 04

    Oct

  • 05

    Oct

  • 30

    Jun

  • 30

    Jun

  • 28

    Sep

ENTA Enanta
$43.43

-0.07 (-0.16%)

07/11/17
JMPS
07/11/17
UPGRADE
JMPS
Outperform
Enanta upgraded on pipeline outlook at JMP Securities
As noted earlier, JMP Securities upgraded Enanta to Outperform from Market Perform. Analyst Liisa Bayko upgraded the stock based on her view of the potential of the company's early stage pipeline and FXR program. Target $40.
07/11/17
JMPS
07/11/17
UPGRADE
JMPS
Outperform
Enanta upgraded to Outperform from Market Perform at JMP Securities
09/14/17
RBCM
09/14/17
INITIATION
Target $54
RBCM
Outperform
Enanta initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Enanta Pharmaceuticals with an Outperform rating and $54 price target.
ADXS Advaxis
$3.91

-0.36 (-8.43%)

11/30/16
CANT
11/30/16
INITIATION
Target $19
CANT
Buy
Advaxis initiated with a Buy at Cantor
Cantor analyst Mara Goldstein initiated Advaxis with a Buy and a $19 price target.
11/30/16
11/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Shutterfly (SFLY) initiated with a Buy at Aegis. 2. WageWorks (WAGE) initiated with a Buy at Chardan. 3. BorgWarner (BWA) initiated with a Buy at Jefferies. 4. Advaxis (ADXS) initiated with a Buy at Cantor. 5. Xtant (XTNT) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AWR American States Water
$50.68

-0.8 (-1.55%)

CDTX Cidara Therapeutics
$8.05

0.2 (2.55%)

07/28/17
WBBS
07/28/17
DOWNGRADE
WBBS
Cidara Therapeutics downgraded to Sell from Hold at WBB Securities
05/25/17
LEER
05/25/17
NO CHANGE
Target $16
LEER
Outperform
Cidara selloff creates favorable risk/reward in Q4 data, says Leerink
Leerink analyst Paul Matteis believes the selloff in shares of Cidara Therapeutics since the company discontinued its CD101 topical program in February creates a favorable risk/reward profile. Read-through to the CD101 IV program, with Phase 2 data coming in Q4, is an error, Matteis tells investors in a research note. Pharmacokinetic, preclinical, safety and historical echinocandin data point to a "solid odds of success" for the IV program, the analyst contends. He raised his CD101 IV odds of success to 60% from 50% and his price target for the shares to $16 from $13. Matteis reiterates an Outperform rating on Cidara.
04/26/17
BTIG
04/26/17
NO CHANGE
Target $20
BTIG
Buy
Cidara Therapeutics price target raised to $20 from $15 at BTIG
BTIG analyst Timothy Chiang raised his price target on Cidara Therapeutics to $20 from $15, as he believes Cidara's once-weekly dosed broad spectrum antifungal agent could become a best-in-class product in the prophylaxis market. Chiang keeps a Buy rating on Cidara shares.
08/11/17
WBBS
08/11/17
UPGRADE
WBBS
Hold
Cidara Therapeutics upgraded to Hold from Sell at WBB Securities
GEMP Gemphire Therapeutics
$9.60

-0.04 (-0.41%)

08/31/17
HCWC
08/31/17
INITIATION
Target $21
HCWC
Buy
Gemphire Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Gemphire Therapeutics with a Buy rating and $21 price target. The share selloff following the ROYAL-1 results is overdone, Acre tells investors in a research note. The company's "novel approach" for nonalcoholic steatohepatitis, including a validated target, has so far been ignored by the Street, the analyst contends.
08/08/17
JEFF
08/08/17
NO CHANGE
Target $18
JEFF
Buy
Gemphire Therapeutics price target lowered to $18 from $32 at Jefferies
Jefferies analyst Matthew Andrews lowered his price target for Gemphire Therapeutics to $18 after reducing his probability of success estimate in heterozygous familial hypercholesterolemia and primary hypercholesterolemia with atherosclerotic cardiovascular disease to 50% from 70%. While gemcabene's absolute reduction of 17.2% is encouraging, the 11.7% placebo-adjusted is below expectations and "somewhat disappointing," Andrews tells investors in a research note. He keeps a Buy rating on Gemphire Therapeutics.
08/08/17
ADAM
08/08/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire Therapeutics weakness overdone, says Canaccord
Canaccord analyst John Newman said Gemphire Therapeutics reported positive top line results for its Phase 2b ROYAL-1 trial, but they were slightly below expectations. He said the safety profile of gemcabene was clean, which is very important going forward. Newman said the recent weakness in the shares is overdone and he reiterated his Buy rating and $31 price target on Gemphire shares.
09/20/17
ADAM
09/20/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire data support commercial viability of gemcabene, says Canaccord
After Gemphire Therapeutics reported that a combined data analysis showed a 21% LDL-C reduction for 600mg gemcabene, Canaccord analyst John Newman said he thinks the data support a clinically meaningful and commercially viable drug. The analyst, who expects gemcabene to continue to show a very clean safety profile and is interested to see if cardiovascular benefit will be part of the efficacy assessment of a Phase 3 trial, keeps a Buy rating and $31 price target on Gemphire shares.
ARRY Array BioPharma
$11.29

-0.03 (-0.27%)

09/11/17
CANT
09/11/17
NO CHANGE
Target $15
CANT
Overweight
Array BioPharma price target raised to $15 from $13 at Cantor
Cantor Fitzgerald analyst Mara Goldstein raised her price target for Array BioPharma to $15 saying the safety lead-in data from the Beacon study show "encouraging signs" of the potential to widen the market potential for binimetinib and encorafenib. These data "lend additional support" for the drugs as best-in-class for the treatment of advanced melanoma, Goldstein tells investors in a research note.The analyst has an Overweight rating on Array shares.
09/11/17
JPMS
09/11/17
NO CHANGE
Target $14
JPMS
Overweight
Array BioPharma price target raised to $14 from $11 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Array BioPharma to $14 following ESMO presentations for the company. Key presentations for Array at the conference include Columbus Part 2 results of binimetinib/encorafenib in BRAF melanoma and binimetinib/encorafenib/cetuximab Beacon results in BRAF colorectal cancer, Rama tells investors in a research note. The focus at ESMO was on Beacon colorectal cancer and the 41% overall response rate observed in the safety lead-in period "meaningfully beat expectations," the analyst writes. He believes Array shares should have rallied more than 7% on Friday. Rama reiterates an Overweight rating on the name.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $14
PIPR
Overweight
Piper reiterates Overweight on Array after 'encouraging' data
Piper Jaffray analyst Edward Tenthoff says Array BioPharma and Pierre Fabre reported "encouraging" Phase III trial results in 30 BRAF-mutant colorectal cancer patients receiving binimetinib, encorafenib and cetuximab. The analyst expects approval of binimetinib and encorafenib in BRAF-mutant melanoma next year. He reiterates an Overweight rating on Array with a $14 price target.
09/20/17
PIPR
09/20/17
NO CHANGE
Target $18
PIPR
Overweight
Array BioPharma price target raised to $18 from $14 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Array BioPharma to $18 and reiterates an Overweight rating on the shares. The company recently strengthened its balance sheet ahead of next summer's approvals, Tenthoff tells investors in a research note. The FDA accepted new drug applications for binimetinib and encorafenib for BRAF-mutant melanoma and the analyst anticipates approval by the June 30 action date.
AUPH Aurinia Pharmaceuticals
$6.11

-0.07 (-1.13%)

09/13/17
ADAM
09/13/17
DOWNGRADE
Target $10
ADAM
Speculative Buy
Aurinia Pharmaceuticals downgraded to Speculative Buy from Buy at Canaccord
Canaccord analyst Neil Maruoka assumed coverage of Aurinia Pharmaceuticals and downgraded the stock to Speculative Buy from Buy, citing the high risks associated with biotech drug development. However, he believes the ongoing Phase III AURORA study has a good chance of success and sees Aurinia as undervalued based on the strength of data generated by voclosporin to date. Maruoka set a $10 price target on Aurinia shares.
03/03/17
HCWC
03/03/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Aurinia Pharmaceuticals to $12 from $8 after the company reported that treatment of lupus nephritis with voclosporin demonstrated a substantial further improvement at 48 weeks. Given this type of "rare" treatment effect change over time, Arce said his conviction has increased that voclosporin can quickly emerge as the new standard-of-care in lupus nephritis treatment and he keeps a Buy rating on Aurinia shares.
04/10/17
CANT
04/10/17
INITIATION
Target $14
CANT
Overweight
Aurinia Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Aurinia Pharmaceuticals with an Overweight and a $14 price target.
03/06/17
03/06/17
NO CHANGE

FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
NEOS Neos Therapeutics
$8.40

-0.3 (-3.45%)

07/31/17
CANT
07/31/17
INITIATION
Target $20
CANT
Overweight
Neos Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Neos Therapeutics with an Overweight rating and $20 price target. The analyst thinks the sales potential of the company's attention-deficit/hyperactivity disorder platform is underappreciated at current share levels.
08/01/17
08/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hain Celestial (HAIN) initiated with a Hold at Loop Capital. 2. Centennial Resource Development (CDEV) initiated with an Overweight at JPMorgan. 3. Neos Therapeutics (NEOS) initiated with an Overweight at Cantor. 4. Celldex (CLDX) assumed with a Buy at H.C. Wainwright. 5. SilverBow Resorces (SBOW) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/17
JMPS
09/18/17
NO CHANGE
Target $30
JMPS
Outperform
JMP says Neos has most complete offering of alternative dose ADHD drugs
JMP Securities analyst Jason Butler said Neos Therapeutics' approval of Adzenys ER Oral Solution further builds out the company's ADHD portfolio, giving it the most complete offering of alternative dose forms of the most widely prescribed drugs used to treat the condition. He keeps an Outperform rating and $30 price target on Neos shares.
09/15/17
BMOC
09/15/17
NO CHANGE
BMOC
Neos' Adzens ER approval 'rounds out ADHD portfolio,' says BMO Capital
BMO Capital analyst Gary Nachman said that while the FDA approval of Adzenys ER which was announced after the close was expected, it was good to see it get "over the goal line," as he believes it will "round out" Neos Therapeutics' ADHD portfolio. Nachman reiterated his Outperform rating and $14 price target on Neos shares.
SELB Selecta Biosciences
$18.66

-0.18 (-0.96%)

12/08/16
STFL
12/08/16
NO CHANGE
STFL
Selecta Biosciences price target raised to $32 from $23 at Stifel
Stifel analyst Thomas Shrader raised his price target on Selecta, saying that data on the company's SEL-212 treatment showed "initial proof of concept in humans with an acceptable safety profile for more serious disease states." He keeps a Buy rating on the shares.
PTGX Protagonist Therapeutics
$16.28

-0.11 (-0.67%)

07/21/17
BTIG
07/21/17
INITIATION
BTIG
Buy
Protagonist Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started coverage of Protagonist with a $36 price target and a Buy rating. The analyst says that the company's oral peptide technology platform "shows promise for treating inflammatory bowel disease." He says that the mechanisms of action of two of the company's drugs "have already been clinically validated by approved treatments for patients that have not adequately responded to TNF-blockers and other existing treatments ."
06/01/17
LEER
06/01/17
NO CHANGE
Target $35
LEER
Outperform
Protagonist Therapeutics price target raised to $35 from $29 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Protagonist Therapeutics to $35 citing the "attractive" partnership for PTG-200. The analyst reiterates an Outperform rating on the shares.
05/30/17
BMOC
05/30/17
NO CHANGE
Target $45
BMOC
Outperform
Protagonist Therapeutics price target raised to $45 on licensing at BMO Capital
BMO Capital analyst Ian Somaiya raised Protagonist Therapeutics' price target to $45 from $34 and reiterated his Overweight rating citing the PGG-200 licensing deal with Janssen. The analyst said the deal increases the probability of clinical and regulatory success in Crohn's and ulcerative colitis and likely reduces the need for future financings.
05/31/17
BMOC
05/31/17
NO CHANGE
BMOC
Protagonist Therapeutics price target raised to $45 from $34 at BMO Capital
BMO Capital analyst M. Ian Somaiya increased his price target on Protagonist (PTGX) after the company reached a licensing deal with Johnson & Johnson (JNJ) for its PTG-200 drug. The analyst says that the deal increases the drug's chances of success , and he calls J&J "an ideal partner." Somaiya keeps an Outperform rating on the stock.
ITCI Intra-Cellular
$19.23

-0.57 (-2.88%)

08/30/17
LTCO
08/30/17
UPGRADE
Target $36
LTCO
Buy
Intra-Cellular upgraded to Buy with $36 target at Ladenburg
Ladenburg Thalmann analyst Christopher James upgraded Intra-Cellular Therapies to Buy from Neutral with a $36 price target. The shares in early trading are up 6%, or 99c, to $16.89. Current studies of lumateperone, which has a better side-effect profile than current schizophrenia medications, appear "sufficient for approval," James told investors earlier in a research note. He believes the drug could reach sales over $1B if Intra-Cellular can secure indications for bipolar depression and agitation in patients with dementia.
09/07/17
PIPR
09/07/17
UPGRADE
PIPR
Overweight
Intra-Cellular upgraded to Overweight from Neutral at Piper Jaffray
09/07/17
09/07/17
UPGRADE
Target $33

Overweight
Intra-Cellular upgraded to Overweight after schizophrenia data at Piper Jaffray
As previously reported, Piper Jaffray analyst Charles Duncan upgraded Intra-Cellular to Overweight from Neutral after the company reported data from its "switching" study of lumateperone in schizophrenia outpatients on approved antipsychotics. He said the trial gives "some of the strongest evidence to date" that lumateperone is differentiated on a range of side effects from the current standard of care. Duncan raised his price target on Intra-Cellular to $33 from $14.
09/08/17
COWN
09/08/17
NO CHANGE
Target $27
COWN
Outperform
Intra-Cellular price target raised to $27 from $20 at Cowen
Cowen analyst Ritu Baral raised her price target on Intra-Cellular to $27 from $20 following the release of top-line Phase 3 switch data on the long-term safety of its lead drug lumateperone in schizophrenia. She is cautious on the meaningfulness of superior efficacy signals but sees them as solid evidence of maintenance of clinical control with lumateperone. Baral maintained her Outperform rating on Intra-Cellular shares.
BLCM Bellicum Pharmaceuticals
$11.54

-0.08 (-0.69%)

03/08/17
WELS
03/08/17
INITIATION
WELS
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Bellicum Pharmaceuticals with an Outperform rating and $28-$31 price target range. The analyst believes the company's "switch technology" to turn cell therapeutics "on" and "off" will be at the forefront of a wave of new therapeutics.
06/23/17
LTCO
06/23/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum selloff after 'strong' data unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li said the updated data Bellicum presented on BPX-501 further strengthens its impressive profile and he sees a high probability for BPX-501 to meet the primary endpoint for an MAA filing. He believes the selloff in the stock as unwarranted and recommends taking advantage to build positions. Li keeps a Buy rating and $31 price target on Bellicum shares.
12/01/16
RAJA
12/01/16
INITIATION
Target $29
RAJA
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Bellicum Pharmaceuticals with an Outperform and a $29 price target.
06/02/17
LTCO
06/02/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum pullback a buying opportunity, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li views the recent pullback in shares of Bellicum Pharmaceuticals as a buying opportunity. The selloff is unwarranted and represents a lack of appreciation of the upcoming highlight of BPX-501 data on June 23, Li tells investors in a research note. The analyst does not see a fundamental event that triggered the selloff in the past week. Li keeps a Buy rating on Bellicum with a $31 price target.
CALA Calithera Biosciences
$15.45

-0.5 (-3.13%)

01/24/17
01/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Buy from Neutral at Citi with analyst Walter Pritchard saying consensus estimates for fiscal 2017 look low. Revenue transition impacted numbers more than the Street realized in 2016, Pritchard tells investors in a research note. The analyst raised his price target for the shares to $64 from $50. 2. Agrium (AGU) upgraded to Outperform from Market Perform at Cowen, while CF Industries (CF), Mosaic (MOS), and Potash (POT) were upgraded to Market Perform from Underperform. 3. Calithera Biosciences (CALA) upgraded to Neutral from Sell at Citi with analyst Robyn Karnauskas citing her conversation with management. Management now appears more open to partnering, Karnauskas tells investors in a research note. 4. Home Bancshares (HOMB) upgraded to Buy from Hold at Sandler O'Neill. 5. Amicus (FOLD) upgraded to Outperform from Neutral at Baird with analyst Michael Ulz saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. Ulz raised his price target to $10 from $7 on Amicus shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/17
LEER
04/03/17
INITIATION
Target $16
LEER
Outperform
Calithera Biosciences reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Calithera Biosciences with an Outperform rating and a $16 price target saying it is well positioned to execute with multiple sources of upside.
01/31/17
RHCO
01/31/17
NO CHANGE
RHCO
Incyte price target raised to $140 from $115 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Incyte (INCY), citing "increased pipeline & technology value" as data releases and PDUFA dates approach. Additionally, the analyst is upbeat on the company's global collaboration deal with Calithera (CALA), saying that the deal expands Incyte's "reach into the (immuno-oncology) space." The analyst reiterates a Buy rating on Incyte.
06/12/17
HCWC
06/12/17
NO CHANGE
Target $19
HCWC
Buy
Calithera Biosciences price target raised to $19 from $14 at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak raised his price target for Calithera Biosciences to $19 saying data suggest CB-1158 "demonstrates promising arginase inhibition." The analyst believes that twice-daily CB-1158 can effectively reduce arginase activity, resulting in "meaningful increases in plasma arginine activity and preliminary evidence of immune modulation." He keeps a Buy rating on Calithera.
INO Inovio
$6.31

0.02 (0.32%)

09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
09/06/17
SBSH
09/06/17
INITIATION
Target $10
SBSH
Buy
Inovio initiated with a Buy at Citi
Citi analyst Joel Beatty started Inovio Pharmaceuticals with a Buy rating and $10 price target. The shares are attractive as the company's differentiated immunotherapy platform has generated strong immune responses that can be used to specifically target a variety of cancers or infectious diseases, the analyst contends.
09/06/17
09/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Caterpillar (CAT) initiated with a Neutral at Seaport Global. 2. Liberty Global (LBTYA) initiated with a Buy at Deutsche Bank. 3. TransUnion (TRU) initiated with a Buy at SunTrust. 4. Inovio (INO) initiated with a Buy at Citi. 5. e.l.f. Beauty (ELF) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
PIPR
06/08/17
UPGRADE
Target $14
PIPR
Overweight
Piper upgrades Inovio to Overweight after lifting of clinical hold
Piper Jaffray analyst Charles Duncan upgraded Inovio Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $14 from $9. The lifting of the clinical hold and Phase III trial start of VGX-3100 reduces risk, Duncan tells investors in a research note. The analyst now has confidence that Inovio's early-stage efforts can eventually move into later-stage.
PRTA Prothena
$63.73

-0.64 (-0.99%)

08/16/17
EVER
08/16/17
INITIATION
EVER
Outperform
Prothena initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Prothena with an Outperform and a $83 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $87
RBCM
Outperform
Prothena initiated with an Outperform at RBC Capital
Target $2RBC Capital analyst Kennen MacKay started Prothena with an Outperform rating and $87 price target.
07/10/17
JEFF
07/10/17
INITIATION
Target $100
JEFF
Buy
Prothena initiated with a Buy at Jefferies
Jefferies initiated Prothena with a Buy and a $100 price target.
07/11/17
JEFF
07/11/17
NO CHANGE
JEFF
Jefferies fundamentally positive on Biotechnology, lists top picks
Jefferies analyst Michael Yee rolled out coverage of 12 Biotechnology names in a 550 page research report. The analyst is "fundamentally positive" on the sector, believing investor interest in large-caps will pick up "as the road to repair slowly continues." He believes the smid-cap space is "becoming a good stock-pickers' market." Yee's top picks in Biotech space include Celgene (CELG), Vertex (VRTX), Spark Therapeutics (ONCE), Prothena (PRTA) and Intercept (ICPT). The analyst's best picks in the smid-cap space are Spark, Prothena, Intercept and FibroGen (FGEN).

TODAY'S FREE FLY STORIES

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

, NKTR

Nektar

$86.45

3 (3.60%)

13:11
02/22/18
02/22
13:11
02/22/18
13:11
Hot Stocks
Analyst cuts Alkermes rating as cancer drug seems less effective than competitor »

Shares of Alkermes (ALKS)…

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

NKTR

Nektar

$86.45

3 (3.60%)

BMY

Bristol-Myers

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 05

    Mar

  • 08

    Mar

  • 04

    Apr

  • 03

    May

CIDM

Cinedigm

$1.25

0.0201 (1.63%)

13:10
02/22/18
02/22
13:10
02/22/18
13:10
Hot Stocks
Cinedigm acquires North American rights to 'Class Rank' »

Cinedigm Corp has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

FB

Facebook

$177.91

1.9 (1.08%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Technical Analysis
Technical Take: Facebook trades near session lows »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

HPQ

HP Inc.

$21.52

0.345 (1.63%)

, LNVGY

Lenovo

$10.15

-0.01 (-0.10%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Earnings
On The Fly: What to watch for in HP Inc.'s earnings report »

HP Inc. (HPQ) is…

HPQ

HP Inc.

$21.52

0.345 (1.63%)

LNVGY

Lenovo

$10.15

-0.01 (-0.10%)

AAPL

Apple

$171.07

-0.78 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 24

    Apr

  • 30

    May

MIC

Macquarie Infrastructure

$39.09

-24.53 (-38.56%)

13:09
02/22/18
02/22
13:09
02/22/18
13:09
Recommendations
Macquarie Infrastructure analyst commentary  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BAMXY

BMW Group

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Hot Stocks
BMW to pay $2.2M to settle DOJ claims of SCRA violations »

The Justice Department…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:05
02/22/18
02/22
13:05
02/22/18
13:05
General news
7-Yr Note Auction Coupon Rate data reported »

7-Yr Note Auction Coupon…

13:05
02/22/18
02/22
13:05
02/22/18
13:05
General news
7-Yr Note Auction Total Amount data reported »

7-Yr Note Auction Total…

W

Wayfair

$74.55

-21.14 (-22.09%)

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Recommendations
Wayfair analyst commentary  »

Citi trims Wayfair target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EAT

Brinker

13:05
02/22/18
02/22
13:05
02/22/18
13:05
Options
Brinker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$33.03

-0.95 (-2.80%)

, VIA

Viacom

$38.35

-1.15 (-2.91%)

13:04
02/22/18
02/22
13:04
02/22/18
13:04
Hot Stocks
SEGA, Paramount announce agreement to co-produce Sonic the Hedgehog feature film »

SEGA Holdings announced…

VIAB

Viacom

$33.03

-0.95 (-2.80%)

VIA

Viacom

$38.35

-1.15 (-2.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

GOOGL

Alphabet Class A

$1,113.75

10.16 (0.92%)

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Technical Analysis
Technical Take: Alphabet Class A moves lower in intraday rounding pattern »

The shares have dropped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DPS

Dr Pepper Snapple

$115.28

-0.1 (-0.09%)

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Options
Dr Pepper Snapple put volume heavy and directionally bearish »

Bearish flow noted in Dr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
02/22/18
02/22
12:55
02/22/18
12:55
General news
Treasury Option Action: a rash of put buying »

Treasury Option Action: a…

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Conference/Events
CFA Society of Milwaukee to hold a luncheon discussion »

Bill Stone, CMT of PNC…

12:55
02/22/18
02/22
12:55
02/22/18
12:55
Conference/Events
STAT Plus to hold webinar »

STAT Senior Science…

GM

General Motors

$41.04

0.4833 (1.19%)

, TM

Toyota

$135.93

1.13 (0.84%)

12:50
02/22/18
02/22
12:50
02/22/18
12:50
Periodicals
GM's Chevy Bolt named in top vehicles list by Consumer Reports, CBS says »

GM's (GM)…

GM

General Motors

$41.04

0.4833 (1.19%)

TM

Toyota

$135.93

1.13 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:50
02/22/18
02/22
12:50
02/22/18
12:50
General news
Treasury 7-year auction preview: the sale should see about average results »

Treasury 7-year auction…

RF

Regions Financial

$19.75

0.13 (0.66%)

12:45
02/22/18
02/22
12:45
02/22/18
12:45
Options
Regions Financial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
02/22/18
02/22
12:45
02/22/18
12:45
General news
Atlanta Fed's Bostic said the Fed is carefully calibrating a return to normalcy »

Atlanta Fed's Bostic…

AAPL

Apple

$171.07

-0.78 (-0.45%)

12:44
02/22/18
02/22
12:44
02/22/18
12:44
Periodicals
Apple picksTrussell as head of production for WVP unit, Deadline reports »

Carol Trussell has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BDRBF

Bombardier

$3.04

-0.06 (-1.94%)

12:44
02/22/18
02/22
12:44
02/22/18
12:44
Periodicals
Bombardier CFO: Used business jet market starting to favor sellers, Reuters says »

Bombardier chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHK

Chesapeake

$3.24

0.605 (23.00%)

, WLL

Whiting Petroleum

$28.55

5.98 (26.50%)

12:39
02/22/18
02/22
12:39
02/22/18
12:39
General news
On The Fly: Top stock stories at midday »

Stocks began the session…

CHK

Chesapeake

$3.24

0.605 (23.00%)

WLL

Whiting Petroleum

$28.55

5.98 (26.50%)

CAR

Avis Budget

$38.96

-0.98 (-2.45%)

HTZ

Hertz

$21.45

3.68 (20.71%)

SGMO

Sangamo

$22.20

-0.05 (-0.22%)

GILD

Gilead

$80.69

-0.25 (-0.31%)

MIC

Macquarie Infrastructure

$39.60

-24.0207 (-37.76%)

AAOI

Applied Optoelectronics

$34.55

1.22 (3.66%)

W

Wayfair

$74.43

-21.26 (-22.22%)

GPOR

Gulfport Energy

$8.41

-0.32 (-3.67%)

DNR

Denbury Resources

$2.33

0.251 (12.07%)

SWN

Southwestern Energy

$3.83

0.325 (9.29%)

PE

Parsley Energy

$24.99

1.885 (8.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 29

    Mar

  • 15

    May

  • 25

    Jun

SGMO

Sangamo

$22.20

-0.05 (-0.22%)

, GILD

Gilead

$80.69

-0.25 (-0.31%)

12:30
02/22/18
02/22
12:30
02/22/18
12:30
Recommendations
Sangamo, Gilead analyst commentary  »

Wells sees…

SGMO

Sangamo

$22.20

-0.05 (-0.22%)

GILD

Gilead

$80.69

-0.25 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SNAP

Snap

$17.34

-1.305 (-7.00%)

12:30
02/22/18
02/22
12:30
02/22/18
12:30
Options
Large three-way spread in SNAP as shares slump »

Large three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.